trichomonas vaginalis

Metronidazole (Metronidazol) is a synthetic nitroimidazole derivative with antiprotozoal and antibacterial activities.

SQ109 (NSC-722041) is an effective inhibitor of the trypomastigote form of the parasite (IC50 = 50 nM). SQ109 is an antitubercular agent and targets MmpL3.

RR-11a analog (aza-peptide Michael acceptor, 7a) is an inhibitor of asparaginyl endopeptidase with IC50s of 4.5 nM, 4.5 nM and 31 nM for AE1 in Trichomonas Vaginalis, AE in Ixodes ricinus and AE in Schistosoma mansoni, respectively.

Sulnidazole, a nitroimidazole derivative, functions as an antiprotozoal compound effective against Trichomonas vaginalis.

Stirimazole, an imidazole derivative, has demonstrated the ability to inhibit Trichomonas vaginalis in vitro at an effective concentration of 0.225 μg ml. In animal studies, an oral dose of 20 mg kg successfully eradicated infectious lesions in mice.

Fexinidazole (HOE 239) is an antiparasitic agent with activity against Trypanosoma cruzi, Tritrichomonas foetus, Trichomonas vaginalis, Entamoeba histolytica, Trypanosoma brucei, and Leishmania donovani. The biologically relevant active metabolites in vivo are the sulfoxide and sulfone.

Coriolin A exhibits activity against gram-positive bacteria, weakly against gram-negative bacteria, as well as yeasts and Trichomonas vaginalis. At a concentration of 5 μg/mL, it inhibits 61.6% of the growth of Yoshida sarcoma, but shows no inhibitory effect on Ehrlich ascites carcinoma in animals.

Granaticin A inhibits the initial stages of RNA biosynthesis and exhibits activity against Gram-positive bacteria, mycobacteria (weak), and Trichomonas vaginalis, as well as tumor cells.

Granaticin B inhibits the initial phase of RNA biosynthesis and exhibits activity against Gram-positive bacteria, mycobacteria (weak), and Trichomonas vaginalis, along with the ability to suppress tumor cells.

Coriolin B exhibits activity against Gram-positive bacteria, weak activity against Gram-negative bacteria, yeast, and Trichomonas vaginalis. At a concentration of 5 μg/mL, Coriolin B inhibits 61.6% of Yoshida sarcoma growth but shows no inhibitory effect on Ehrlich ascites carcinoma in animals.

Coriolin C displays activity against Gram-positive bacteria, weakly against Gram-negative bacteria, as well as yeast and Trichomonas vaginalis. At a concentration of 5 μg/mL, Coriolin C can inhibit 61.6% of the growth of Yoshida sarcoma, though it does not affect Ehrlich ascites carcinoma in animals.

5'-Azido-5'-deoxyadenosine is a purine nucleoside analogue containing an azide group, exhibiting inhibitory activity against Trichomonas vaginalis and PRMT5, and capable of undergoing click chemistry reactions with molecules containing alkyne, DBCO, or BCN groups.

LL-37 FK-13 TFA, the TFA salt form of LL-37 FK-13, is an antimicrobial agent that inhibits Trichomonas vaginalis. It exhibits minimal hemolytic effects on human red blood cells and shows slight cytotoxicity towards human fibroblasts.